A more precise diagnosis of autism and other neurological disorders may be possible. NeuroPointDX is performing research to develop a blood test which can provide earlier diagnosis and more precise treatment of autism spectrum disorders (ASD) based on the child’s own metabolism.
NeuroPointDX, through its compound safety screening division Stemina Biomarker Discovery, has developed the leading metabolomics platform for identifying differences in metabolism in children with ASD and other neurological disorders.
NeuroPointDX has discovered differences in small molecules in the blood of children with ASD that may allow earlier diagnosis and more precise treatment of children across the spectrum. NeuroPointDX is validating these markers and bringing its diagnostic test to market through its ongoing clinical study the Children’s Autism Metabolome Project (CAMP).